Sihuan Bio has released its 2026 interim report, with net profit attributable to the parent company at a loss of 25.83 million yuan, an increase in loss of 15.73 million yuan compared with the same period last year. The company's total operating revenue was 111 million yuan, down 39.12 percent year on year, and net cash flow from operating activities was a negative 17.27 million yuan, down 134.43 percent year on year. The company's latest asset-liability ratio was 28.00 percent, gross margin was 20.57 percent, return on equity was negative 8.37 percent, and diluted earnings per share was negative 0.03 yuan.
Jiangsu Sihuan Bioengineering Co LtdNet loss widened and revenue fell sharply in interim report
